{
  "docId": "019de076-7b67-762e-8b55-8f35aa9a2cc0",
  "docSlug": "7d5a5b546ee496a809a6ede1a6c2c260",
  "documentTitle": "Equillium | Investor Presentation Deck | 32 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 32,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a column-based layout to compare four distinct medical conditions, each with specific patient counts and development milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-7b67-762e-8b55-8f35aa9a2cc0/18",
  "deckHref": "/decks/019de076-7b67-762e-8b55-8f35aa9a2cc0",
  "deckJsonHref": "/decks/019de076-7b67-762e-8b55-8f35aa9a2cc0.json",
  "deckAnchorHref": "/decks/019de076-7b67-762e-8b55-8f35aa9a2cc0#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.115,
        "w": 0.926,
        "x": 0.037,
        "y": 0.175
      },
      "kind": "callout",
      "text": "Multi-Billion dollar market opportunity for EQ101 in medical dermatology. Large need exists for safe and effective therapies",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c502bb4-290d-4dd7-9795-1f506fc2d3e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.21,
        "x": 0.037,
        "y": 0.33
      },
      "kind": "list",
      "text": "Cutaneous T cell Lymphoma: 24,000 adult US Patients; PoC Achieved, Phase 2/3 Ready, Open IND; Unmet need for safe and effective therapies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b9a3dd4-8812-4ef3-a8b0-388178ba6d7e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.21,
        "x": 0.525,
        "y": 0.33
      },
      "kind": "list",
      "text": "Vitiligo: 1.5M+ US Patients; Future Opportunity; Only one FDA approval: JAKi; Late-stage Industry pipeline predominantly JAKi",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92277cc9-de15-43dc-b7b7-b2ba6bc2a5b9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.21,
        "x": 0.78,
        "y": 0.33
      },
      "kind": "list",
      "text": "Atopic Dermatitis: 6.6M US moderate-severe Patients; Future Opportunity; 3 FDA approved JAKi; Large refractory population in need of safe treatment alternatives",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3f42601-9d7c-4848-90bf-5bc8a470eba6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.21,
        "x": 0.265,
        "y": 0.33
      },
      "kind": "list",
      "text": "Alopecia Areata: 250,000 US moderate-severe Patients; Phase 2 Study ongoing; Only two FDA approvals: JAKi; Late-stage Industry pipeline predominantly JAKi",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f66c03e4-8fe8-4cc2-85d4-64725be28937",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.125,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1) Kx Advisors 2) Benigno, Clin Cosmet Investig Dermatol, 2020 3) Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology. 2020 4) Chiesa Fuxench ZC, J Invest Dermatol. 2019",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8ddb09a-8d29-4041-a443-5d6f08b96f5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.713,
        "x": 0.037,
        "y": 0.075
      },
      "kind": "title",
      "text": "EQ101: Valuable Medical Dermatology Franchise",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "20f2b42f-b289-42b7-9f4e-58dad27f2421",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "98c098a1-bb17-428a-bb8f-3034ec8b03e1",
      "evidence": "list/bullet: Atopic Dermatitis: 6.6M US moderate-severe Patients; Future Opportunity; 3 FDA approved JAKi; Large refractory population in need of safe treatment alternatives",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 23,
      "from": 5,
      "beatId": "ad87164c-eefb-4286-988c-3da24e7ea3ff",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 5-23 present Equillium's platform and pipeline as a solution to the problems identified, providing relief for patients with immunological disorders.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}